Literature DB >> 6837601

Relapses after interruption of cyanocobalamin therapy in patients with pernicious anemia.

D Savage, J Lindenbaum.   

Abstract

One or more episodes of recurrent megaloblastic anemia occurred in 36 (10.8 percent) of 333 patients with pernicious anemia following interruption of therapy. Treatment had most commonly been discontinued by patients because they felt well, or by physicians due to error. Thirty-five episodes of recurrent cobalamin deficiency were analyzed in detail. In the 24 patients in whom the exact date of cessation of therapy was recorded, the mean interval before relapse was diagnosed was 64.5 months (range 21 to 123 months). Recurrence manifested as macrocytosis in the absence of anemia occurred earlier (mean, 49.2 months) than that associated with anemia (73.1 months). A weak correlation was apparent between the amount of previous cyanocobalamin treatment and time to relapse. One third of relapses were unrecognized and left untreated for more than two years, while usually slow hematologic progression occurred. Recurrences of cobalamin deficiency in individual patients exhibited mimetic features. Further study is necessary to establish the optimal dosage and frequency of maintenance therapy in pernicious anemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6837601     DOI: 10.1016/0002-9343(83)91064-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  How I treat cobalamin (vitamin B12) deficiency.

Authors:  Ralph Carmel
Journal:  Blood       Date:  2008-07-07       Impact factor: 22.113

2.  Low serum cobalamin levels in a population study of 70- and 75-year-old subjects. Gastrointestinal causes and hematological effects.

Authors:  H Nilsson-Ehle; S Landahl; G Lindstedt; L Netterblad; R Stockbruegger; J Westin; C Ahren
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

3.  Vitamin B12 injections versus oral supplements. How much money could be saved by switching from injections to pills?

Authors:  C van Walraven; P Austin; C D Naylor
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.